The overarching complexity of retina diseases (Wet AMD - DME - RVO - mCNV) makes it challenging to diagnose and manage accurately. The development of new drugs provides a ray of hope for more effective treatment of these widely prevalent and debilitating diseases. Capitalizing on our unique expertise in the retina market and in patient chart-based research, we have designed, with input from our clients, a new syndicated offering based on real world data to monitor the impact of the new treatments on Wet AMD, DME, RVO, and mCNV management.
Fill in the form below to access an overview of our Multiple Myeloma syndicated study including:
- Types of data collected
- Dates of research waves